Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

NCT06783153 is registered in ClinicalTrials.gov with Mansoura University as lead sponsor.

NCT NCT06783153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06783153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Lead sponsor
Mansoura University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 20, 2025
Completion date
December 31, 2025
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute radiation enteritis, bladder (urothelial, transitional cell) cancer, cervical adenocarcinoma, pelvic radiotherapy, prostate cancer, radiotherapy induced diarrhea, rectal adenocarcinoma, rifaximin